CTP 499

Drug Profile

CTP 499

Alternative Names: CTP-499

Latest Information Update: 07 Nov 2015

Price : $50

At a glance

  • Originator Concert Pharmaceuticals
  • Class Anti-inflammatories; Antifibrotics; Organic deuterium compounds; Small molecules
  • Mechanism of Action Antioxidants; Phosphoric diester hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Diabetic nephropathies

Highest Development Phases

  • Phase II Diabetic nephropathies
  • Phase I Kidney disorders

Most Recent Events

  • 30 Sep 2015 Concert Pharmaceuticals and US FDA agree on Special Protocol Assessment for a phase III trial of CTP 499 in Diabetic nephropathies before September 2015
  • 21 Jul 2015 Phase II development for Diabetic nephropathies is ongoing in the US
  • 15 Nov 2014 CTP 499 is available for licensing as of 15 Nov 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top